New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
06:18 EDTPACBPacific Biosciences upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded Pacific Biosciences to Neutral citing valuation and stronger system placements following the company's Q1 results. The firm has a $7 price target for shares.
News For PACB From The Last 14 Days
Check below for free stories on PACB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
16:12 EDTPACBPacific Biosciences reports Q2 EPS (27c), consensus (28c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use